Home / Johnson & Johnson (JNJ)
Stock Analysis
Johnson & Johnson (JNJ)
235.66 -2.16%
Updated: 2026-06-16 10:51 UTC
Technology-style analysis layer: price structure, momentum, key levels and business quality in one view.
WOI Investment Thesis
Constructive
Momentum: Neutral
Range: 87% of 52W range
Bull254.31
Base248.56
Bear231.47
Key Levels
Resistance248.56
Support231.47
InvalidationBelow 231.47
Upside Target254.31
Price Chart
JNJ ยท Interactive chart workspace
Open Full Workspace
What's Driving JNJ?
๐Ÿ“ˆ Technical recovery is improving
Momentum is Neutral. The main decision zone is framed by resistance near 248.56 and support near 231.47.
๐Ÿ’ผ Business quality remains relevant
The setup is supported by the latest fundamentals snapshot. Use the Business Lens card for revenue, profitability and balance sheet context.
โš ๏ธ Key risk remains
Below 231.47
Full Analysis Workspace
Technical Setup
๐Ÿ”บ Technical Setup
Pattern
Triangle Compression / SYM / UP
State
Active
Trigger
230.48
Target
254.31
Risk / Invalid
221.18
Compression
66%
๐ŸŽฏ Decision Map
The next meaningful technical decision is likely to occur between support at 231.47 and resistance at 251.12. A cleaner push through resistance would improve continuation odds, while a loss of support would weaken the current thesis. Pattern invalidation sits near 213.76, so a violation there would materially change the current setup narrative.
Business Lens
๐Ÿ’ผ Fundamentals Snapshot
Source: sec
๐Ÿ’ผ Business Lens
QUALITY VIEW
Financial quality snapshot
Financial context is mixed
๐Ÿ“ˆ Growth: Improving ๐Ÿ’ฐ Profit: Positive ๐Ÿ’ต Cash: Pressured ๐Ÿ›ก Balance: Mixed
โ€ข Quarterly revenue is improving again after a softer stretch.
โ€ข Quarterly profitability is positive, though margins are not especially strong.
๐Ÿ’ต Revenue
24.06B
๐Ÿ“ˆ Net Income
5.24B
๐Ÿงฎ EPS (Basic)
2.17
๐Ÿข Company
Johnson & Johnson
๐Ÿท Sector
Healthcare
๐Ÿงฉ Industry
Pharma
Related Stocks
Compare with related stocks
Same sector and industry ideas for deeper research
AbbVie (ABBV) technical analysisAstrazeneca (AZN) technical analysisBristol-Myers Squibb Company (BMY) technical analysisELI LILLY & Co (LLY) technical analysisMerck & Co (MRK) technical analysisPfizer (PFE) technical analysisTeva Pharmaceutical Industries (TEVA) technical analysis
Note: This is an algorithmic technical snapshot, not financial advice.